Cargando…

Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS

BACKGROUND: There are limited therapeutic options directed at the underlying pathological processes in acute respiratory distress syndrome (ARDS). Experimental therapeutic strategies have targeted the protective systems that become deranged in ARDS such as surfactant. Although results of surfactant...

Descripción completa

Detalles Bibliográficos
Autores principales: Qaqish, Robert, Watanabe, Yui, Galasso, Marcos, Summers, Cara, Ali, A adil, Takahashi, Mamoru, Gazzalle, Anajara, Liu, Mingyao, Keshavjee, Shaf, Cypel, Marcelo, Del Sorbo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591687/
https://www.ncbi.nlm.nih.gov/pubmed/33108583
http://dx.doi.org/10.1186/s40635-020-00352-w
_version_ 1783601035446583296
author Qaqish, Robert
Watanabe, Yui
Galasso, Marcos
Summers, Cara
Ali, A adil
Takahashi, Mamoru
Gazzalle, Anajara
Liu, Mingyao
Keshavjee, Shaf
Cypel, Marcelo
Del Sorbo, Lorenzo
author_facet Qaqish, Robert
Watanabe, Yui
Galasso, Marcos
Summers, Cara
Ali, A adil
Takahashi, Mamoru
Gazzalle, Anajara
Liu, Mingyao
Keshavjee, Shaf
Cypel, Marcelo
Del Sorbo, Lorenzo
author_sort Qaqish, Robert
collection PubMed
description BACKGROUND: There are limited therapeutic options directed at the underlying pathological processes in acute respiratory distress syndrome (ARDS). Experimental therapeutic strategies have targeted the protective systems that become deranged in ARDS such as surfactant. Although results of surfactant replacement therapy (SRT) in ARDS have been mixed, questions remain incompletely answered regarding timing and dosing strategies of surfactant. Furthermore, there are only few truly clinically relevant ARDS models in the literature. The primary aim of our study was to create a clinically relevant, reproducible model of severe ARDS requiring extracorporeal membrane oxygenation (ECMO). Secondly, we sought to use this model as a platform to evaluate a bronchoscopic intervention that involved saline lavage and SRT. METHODS: Yorkshire pigs were tracheostomized and cannulated for veno-venous ECMO support, then subsequently given lung injury using gastric juice via bronchoscopy. Animals were randomized post-injury to either receive bronchoscopic saline lavage combined with SRT and recruitment maneuvers (treatment, n = 5) or recruitment maneuvers alone (control, n = 5) during ECMO. RESULTS: PaO(2)/FiO(2) after aspiration injury was 62.6 ± 8 mmHg and 60.9 ± 9.6 mmHg in the control and treatment group, respectively (p = 0.95) satisfying criteria for severe ARDS. ECMO reversed the severe hypoxemia. After treatment with saline lavage and SRT during ECMO, lung physiologic and hemodynamic parameters were not significantly different between treatment and controls. CONCLUSIONS: A clinically relevant severe ARDS pig model requiring ECMO was established. Bronchoscopic saline lavage and SRT during ECMO did not provide a significant physiologic benefit compared to controls.
format Online
Article
Text
id pubmed-7591687
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-75916872020-10-30 Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS Qaqish, Robert Watanabe, Yui Galasso, Marcos Summers, Cara Ali, A adil Takahashi, Mamoru Gazzalle, Anajara Liu, Mingyao Keshavjee, Shaf Cypel, Marcelo Del Sorbo, Lorenzo Intensive Care Med Exp Research BACKGROUND: There are limited therapeutic options directed at the underlying pathological processes in acute respiratory distress syndrome (ARDS). Experimental therapeutic strategies have targeted the protective systems that become deranged in ARDS such as surfactant. Although results of surfactant replacement therapy (SRT) in ARDS have been mixed, questions remain incompletely answered regarding timing and dosing strategies of surfactant. Furthermore, there are only few truly clinically relevant ARDS models in the literature. The primary aim of our study was to create a clinically relevant, reproducible model of severe ARDS requiring extracorporeal membrane oxygenation (ECMO). Secondly, we sought to use this model as a platform to evaluate a bronchoscopic intervention that involved saline lavage and SRT. METHODS: Yorkshire pigs were tracheostomized and cannulated for veno-venous ECMO support, then subsequently given lung injury using gastric juice via bronchoscopy. Animals were randomized post-injury to either receive bronchoscopic saline lavage combined with SRT and recruitment maneuvers (treatment, n = 5) or recruitment maneuvers alone (control, n = 5) during ECMO. RESULTS: PaO(2)/FiO(2) after aspiration injury was 62.6 ± 8 mmHg and 60.9 ± 9.6 mmHg in the control and treatment group, respectively (p = 0.95) satisfying criteria for severe ARDS. ECMO reversed the severe hypoxemia. After treatment with saline lavage and SRT during ECMO, lung physiologic and hemodynamic parameters were not significantly different between treatment and controls. CONCLUSIONS: A clinically relevant severe ARDS pig model requiring ECMO was established. Bronchoscopic saline lavage and SRT during ECMO did not provide a significant physiologic benefit compared to controls. Springer International Publishing 2020-10-27 /pmc/articles/PMC7591687/ /pubmed/33108583 http://dx.doi.org/10.1186/s40635-020-00352-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Qaqish, Robert
Watanabe, Yui
Galasso, Marcos
Summers, Cara
Ali, A adil
Takahashi, Mamoru
Gazzalle, Anajara
Liu, Mingyao
Keshavjee, Shaf
Cypel, Marcelo
Del Sorbo, Lorenzo
Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title_full Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title_fullStr Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title_full_unstemmed Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title_short Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
title_sort veno-venous ecmo as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ards
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591687/
https://www.ncbi.nlm.nih.gov/pubmed/33108583
http://dx.doi.org/10.1186/s40635-020-00352-w
work_keys_str_mv AT qaqishrobert venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT watanabeyui venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT galassomarcos venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT summerscara venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT aliaadil venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT takahashimamoru venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT gazzalleanajara venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT liumingyao venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT keshavjeeshaf venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT cypelmarcelo venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards
AT delsorbolorenzo venovenousecmoasaplatformtoevaluatelunglavageandsurfactantreplacementtherapyinananimalmodelofsevereards